# SCRIMED Pilot Value Evidence Brief

Status: pilot-value-evidence-packets-active-synthetic-no-commercial-guarantee
Updated: 2026-07-09
Evidence artifacts: 8
Evidence packets: 5
Reviewer checkpoints: 5
Claim controls: 7
Average evidence score: 92

## Boundary
SCRIMED Pilot Value Evidence packages synthetic-only value metrics into buyer-ready pilot packets, acceptance criteria, reviewer checkpoints, and claim controls. It does not authorize live PHI, autonomous clinical care, diagnosis, treatment, prescribing, patient outreach, payer submission, EHR writeback, final imaging interpretation, production deployment, customer activation, certification claims, audited financial reporting, valuation assurance, revenue guarantees, profit guarantees, ROI guarantees, or binding commercial offers.

This brief is synthetic-only pilot value evidence. It does not authorize live PHI, autonomous clinical care, diagnosis, treatment, prescribing, patient outreach, payer submission, EHR writeback, final imaging interpretation, production deployment, customer activation, certification claims, audited financial reporting, valuation assurance, revenue guarantees, profit guarantees, ROI guarantees, or binding commercial offers.

## Evidence Packets
- Workflow discovery evidence packet (30-day, Clinical operations and CMIO): Turn documentation and missing-evidence pain into a measurable no-PHI discovery scope. Boundary: Not an ROI guarantee, audited labor-savings report, or clinical outcome claim.
- RCM documentation evidence packet (60-day, RCM and prior authorization teams): Show documentation completeness and denial-review readiness without payer submission. Boundary: No payer submission, billing submission, coverage determination, or reimbursement guarantee.
- Patient access evidence packet (60-day, Patient access and care coordination): Show referral and follow-up risk visibility without patient outreach or scheduling authority. Boundary: No live patient outreach, scheduling command, care-plan modification, or patient-specific medical advice.
- Interoperability diligence packet (90-day, CIO, security, integration teams): Convert healthcare IT complexity into a standards, source-contract, and approval evidence map. Boundary: Not production connector approval, EHR writeback, raw schema review, or live PHI authorization.
- Investor diligence evidence packet (90-day, Angel, strategic, private, clinic, and partner investors): Turn product, proof, route, safety, and commercial readiness signals into a claims-safe diligence package. Boundary: Not securities material, valuation assurance, investment advice, certification, or customer go-live approval.

## Evidence Artifacts
- Workflow baseline proxy (pilot-scope-ready, score 93): Compare synthetic baseline artifact against the human-reviewed SCRIMED packet completion record. Review: Reviewer must approve metric interpretation before external sharing.
- Prior authorization evidence map (review-ready, score 94): Track evidence coverage, missing fields, source references, and reviewer signoff. Review: Human approval required before any payer-facing use.
- Referral delay proof packet (pilot-scope-ready, score 89): Measure synthetic time-to-review, missing packet detection, and owner assignment completeness. Review: Human review and consent pathway required before any live outreach.
- Interoperability readiness matrix (external-approval-required, score 92): Score interface inventory, source contract completeness, security owner coverage, and blocked writeback controls. Review: External technical approval required before live connector implementation.
- Agent trace diligence proof (review-ready, score 96): Score trace field completeness, policy decision coverage, blocked action clarity, and audit hash presence. Review: Reviewer must confirm no token, PHI, or raw connector payload is exposed.

## Reviewer Checkpoints
- Clinical reviewer: Clinical-facing artifacts are decision-support and education only. Pass: No diagnosis, treatment, prescribing, triage, or live-care language appears. Fail closed: Block packet promotion and route to clinical authority readiness.
- Finance reviewer: Value evidence is not represented as audited savings, revenue, profit, or ROI. Pass: All metrics are labeled proxy, synthetic, or measurement framework evidence. Fail closed: Remove financial claim and require qualified finance review.
- RCM compliance reviewer: RCM artifacts do not imply payer submission, claim submission, or coverage determination. Pass: Draft-only and human-review language is present. Fail closed: Block RCM packet distribution until corrected.
- Integration security reviewer: Interoperability artifacts do not expose raw schemas, raw connector payloads, or writeback authority. Pass: Synthetic metadata and external approval blockers are visible. Fail closed: Move packet to external-approval-required.
- Founder or diligence owner: Buyer or investor packet is safe to distribute. Pass: No secrets, PHI, token values, certification claims, valuation assurance, or customer go-live statements. Fail closed: Hold packet in internal review and refresh proof routes.

## Claim Controls
- ROI overclaim: block "ROI guarantee" and use "synthetic value hypothesis with reviewer-gated measurement plan" with baseline proxy, target direction, proof route, and reviewer signoff.
- Revenue overclaim: block "revenue guarantee" and use "commercial readiness signal" with pilot scope, buyer segment, offer path, and retained boundary.
- Clinical authority overclaim: block "clinical outcome guarantee" and use "decision-support workflow readiness" with clinical reviewer checkpoint and no-live-care boundary.
- Payer workflow overclaim: block "payer submission authority" and use "draft documentation completeness review" with human review gate and blocked-submission state.
- Integration overclaim: block "production connector approved" and use "synthetic interoperability discovery complete" with standards map, approval owner, and no-writeback boundary.
- Investor overclaim: block "valuation assurance" and use "diligence readiness evidence" with dated proof manifest, risk register link, and qualified-review note.
- Customer activation overclaim: block "customer activation authority" and use "pilot-readiness packet prepared for review" with acceptance criteria, reviewer gate, and no-production-authorization header.

Next best move: Attach the highest-fit packet to a buyer segment, demo route, acceptance criteria, reviewer checkpoint, and no-authority distribution gate before external sharing.